CC48 a new CB2R agonist/FAAH inhibitor dual drug blocks gastric cancer progression and overcomes paclitaxel resistance.

J Exp Clin Cancer Res · 2025 · PMC12265377 · PMID 40665405

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

A decreasing trend in migration was also observed with 10 μM CC48 (0.6 vs. 1); by contrast, no effect was observed with ASF151 at both concentrations used.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.